Genotype distributions and allele frequencies of +896A/G TLR4 and CCR5WT/Δ32 SNPs in 110 TAV patients and 128 controls (2 × 2 comparisons between the different groups with OR and 95% CI)
| Candidate genes . | Reference SNP number . | Candidate SNPs . | TAV patients (N = 110) (%) . | Controls (N = 128) (%) . | P (3 × 2, 2 × 2 tables) . | OR (95% CI); P-value . |
|---|---|---|---|---|---|---|
| TLR4 | rs4986790 | +896A/A | 88 (80) | 119 (81) | 0.01 | 3.2 (1.5–6.6); 0.0008 |
| +896A/G | 15 (14) | 7 (12) | ||||
| +896G/G | 7 (6) | 2 (7) | ||||
| +896A | 191 (75) | 235 (92) | 0.0008 | |||
| +896G | 29 (25) | 11 (8) | ||||
| CCR5 | rs333 | WT/WT | 108 (98) | 114 (89) | 0.01 | 4.08 (1.3–12.8); 0.007 |
| WT/Δ32 | 2 (2) | 10 (8) | ||||
| Δ32/Δ32 | 0 (0) | 4 (3) | ||||
| WT | 216 (98) | 238 (93) | 0.006 | |||
| Δ32 | 4 (2) | 18 (7) |
| Candidate genes . | Reference SNP number . | Candidate SNPs . | TAV patients (N = 110) (%) . | Controls (N = 128) (%) . | P (3 × 2, 2 × 2 tables) . | OR (95% CI); P-value . |
|---|---|---|---|---|---|---|
| TLR4 | rs4986790 | +896A/A | 88 (80) | 119 (81) | 0.01 | 3.2 (1.5–6.6); 0.0008 |
| +896A/G | 15 (14) | 7 (12) | ||||
| +896G/G | 7 (6) | 2 (7) | ||||
| +896A | 191 (75) | 235 (92) | 0.0008 | |||
| +896G | 29 (25) | 11 (8) | ||||
| CCR5 | rs333 | WT/WT | 108 (98) | 114 (89) | 0.01 | 4.08 (1.3–12.8); 0.007 |
| WT/Δ32 | 2 (2) | 10 (8) | ||||
| Δ32/Δ32 | 0 (0) | 4 (3) | ||||
| WT | 216 (98) | 238 (93) | 0.006 | |||
| Δ32 | 4 (2) | 18 (7) |
All genotypes were in Hardy–Weinberg equilibrium.
P = significance values calculated by the χ2 test, analysing the data of these SNPs between TAV patients and controls.
OR = OR value calculated, analysing the data between TAV patients and controls.
TLR4: Toll-like receptor-4; CCR5: CC-chemokine receptor-5.
Genotype distributions and allele frequencies of +896A/G TLR4 and CCR5WT/Δ32 SNPs in 110 TAV patients and 128 controls (2 × 2 comparisons between the different groups with OR and 95% CI)
| Candidate genes . | Reference SNP number . | Candidate SNPs . | TAV patients (N = 110) (%) . | Controls (N = 128) (%) . | P (3 × 2, 2 × 2 tables) . | OR (95% CI); P-value . |
|---|---|---|---|---|---|---|
| TLR4 | rs4986790 | +896A/A | 88 (80) | 119 (81) | 0.01 | 3.2 (1.5–6.6); 0.0008 |
| +896A/G | 15 (14) | 7 (12) | ||||
| +896G/G | 7 (6) | 2 (7) | ||||
| +896A | 191 (75) | 235 (92) | 0.0008 | |||
| +896G | 29 (25) | 11 (8) | ||||
| CCR5 | rs333 | WT/WT | 108 (98) | 114 (89) | 0.01 | 4.08 (1.3–12.8); 0.007 |
| WT/Δ32 | 2 (2) | 10 (8) | ||||
| Δ32/Δ32 | 0 (0) | 4 (3) | ||||
| WT | 216 (98) | 238 (93) | 0.006 | |||
| Δ32 | 4 (2) | 18 (7) |
| Candidate genes . | Reference SNP number . | Candidate SNPs . | TAV patients (N = 110) (%) . | Controls (N = 128) (%) . | P (3 × 2, 2 × 2 tables) . | OR (95% CI); P-value . |
|---|---|---|---|---|---|---|
| TLR4 | rs4986790 | +896A/A | 88 (80) | 119 (81) | 0.01 | 3.2 (1.5–6.6); 0.0008 |
| +896A/G | 15 (14) | 7 (12) | ||||
| +896G/G | 7 (6) | 2 (7) | ||||
| +896A | 191 (75) | 235 (92) | 0.0008 | |||
| +896G | 29 (25) | 11 (8) | ||||
| CCR5 | rs333 | WT/WT | 108 (98) | 114 (89) | 0.01 | 4.08 (1.3–12.8); 0.007 |
| WT/Δ32 | 2 (2) | 10 (8) | ||||
| Δ32/Δ32 | 0 (0) | 4 (3) | ||||
| WT | 216 (98) | 238 (93) | 0.006 | |||
| Δ32 | 4 (2) | 18 (7) |
All genotypes were in Hardy–Weinberg equilibrium.
P = significance values calculated by the χ2 test, analysing the data of these SNPs between TAV patients and controls.
OR = OR value calculated, analysing the data between TAV patients and controls.
TLR4: Toll-like receptor-4; CCR5: CC-chemokine receptor-5.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
